trial

Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia

NCTId NCT00833547
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 25 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2012-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
25 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-09
Primary completion
2012-09
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
eszopiclone

Sponsors

Massachusetts General HospitalLead Sponsor
Sumitomo Pharmaceuticals AmericaCollaborator
Beth Israel Deaconess Medical CenterCollaborator

Investigators

1
Dara S. Manoach, PhDPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
25
Phase
NA
Primary Completion Date
2012-09
Status
COMPLETED
relationships
The graph out of here
drug
eszopiclone
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
Sumitomo Pharmaceuticals America
company
Beth Israel Deaconess Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dara S. Manoach, PhD
person